Valerie A. White

Valerie A. White

Auto-generated profile, based on publicly available information

Valerie A. White

International Agency for Research on Cancer (IARC), World Health Organization, 69372 Lyon, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
LULesley Uttley
Lesley Uttley
BRBlanca Iciar Indave Ruiz
Blanca Iciar Indave Ruiz
CHChris Hyde
Chris Hyde
VWValerie White
Valerie White
DLDilani Lokuhetty
Dilani Lokuhetty
ICIan Cree
Ian Cree
Click on the article title to read more.

16 May 2019 in Ocular Oncology and Pathology
Verified
Journal Article
Open access
PDF file
VWValerie A. White
Valerie A. White
Background: Lymphomas that involve the tissues of the ocular adnexae and the eye itself can be confusing for both the new and seasoned learner alike. In this review, I present a simple way of classifying these disorders that will help to facilitate understanding of these myriad entities. Summary: Classifications of lymphomas have changed significantly over the last 40 years, but in recent decades, the basic structure of the WHO classification has remained the same, facilitating understanding. Key Messages: The ocular lymphomas can be divided into those that are external to the eye (ocular adnexae) and those that are internal (vitreoretinal and uveal). At each of these sites specific subtypes of lymphoma are common. Focusing on these common subtypes can aid the learner to create a scaffold that enables current understanding and upon which they can build for the future.

Verified
Journal Article
Open access
PDF file
JTJulia Thierauf
Julia Thierauf
AFAlex A. Farahani
Alex A. Farahani
BRBlanca Iciar Indave Ruiz
Blanca Iciar Indave Ruiz
ABAdam Z. Bard
Adam Z. Bard
VWValerie A. White
Valerie A. White
JLJochen K Lennerz
Jochen K Lennerz
Mucoepidermoid carcinoma (MEC) is often seen in salivary glands and can harbor MAML2 translocations (MAML2+). The translocation status has diagnostic utility as an objective confirmation of the MEC diagnosis, for example, when distinction from the more aggressive adenosquamous carcinoma (ASC) is not straightforward. To assess the diagnostic relevance of MAML2, we examined our 5-year experience in prospective testing of 8106 solid tumors using RNA-seq panel testing in combinations with a two-round Delphi-based scenario survey. The prevalence of MAML2+ across all tumors was 0.28% (n = 23/8106) and the majority of MAML2+ cases were found in head and neck tumors (78.3%), where the overall prevalence was 5.9% (n = 18/307). The sensitivity of MAML2 for MEC was 60% and most cases (80%) were submitted for diagnostic confirmation; in 24% of cases, the MAML2 results changed the working diagnosis. An independent survey of 15 experts showed relative importance indexes of 0.8 and 0.65 for “confirmatory MAML2 testing” in suspected MEC and ASC, respectively. Real-world evidence confirmed that the added value of MAML2 is a composite of an imperfect confirmation test for MEC and a highly specific exclusion tool for the diagnosis of ASC. Real-world evidence can help move a rare molecular-genetic biomarker from an emerging tool to the clinic.